[go: up one dir, main page]

BRPI0817265A2 - Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada - Google Patents

Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada

Info

Publication number
BRPI0817265A2
BRPI0817265A2 BRPI0817265-0A BRPI0817265A BRPI0817265A2 BR PI0817265 A2 BRPI0817265 A2 BR PI0817265A2 BR PI0817265 A BRPI0817265 A BR PI0817265A BR PI0817265 A2 BRPI0817265 A2 BR PI0817265A2
Authority
BR
Brazil
Prior art keywords
rna
rna molecule
vaccine
isolated
molecule
Prior art date
Application number
BRPI0817265-0A
Other languages
English (en)
Inventor
Josef Thalhamer
Richard Weiss
Sandra Scheiblhofer
Angelika Frühwirth
Original Assignee
Biomay Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomay Ag filed Critical Biomay Ag
Publication of BRPI0817265A2 publication Critical patent/BRPI0817265A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0817265-0A 2007-09-28 2008-09-29 Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada BRPI0817265A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07450169A EP2042193A1 (en) 2007-09-28 2007-09-28 RNA Vaccines
PCT/EP2008/063035 WO2009040443A1 (en) 2007-09-28 2008-09-29 Rna vaccines

Publications (1)

Publication Number Publication Date
BRPI0817265A2 true BRPI0817265A2 (pt) 2015-06-16

Family

ID=38847002

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817265-0A BRPI0817265A2 (pt) 2007-09-28 2008-09-29 Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada

Country Status (11)

Country Link
US (3) US20110033416A1 (pt)
EP (2) EP2042193A1 (pt)
JP (1) JP5535920B2 (pt)
CN (1) CN101827606B (pt)
AU (1) AU2008303483B2 (pt)
BR (1) BRPI0817265A2 (pt)
CA (1) CA2700604C (pt)
DK (1) DK2200646T3 (pt)
ES (1) ES2434221T3 (pt)
PL (1) PL2200646T3 (pt)
WO (1) WO2009040443A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
JP5705113B2 (ja) 2008-08-15 2015-04-22 サーカッシア リミテッド Ｉｌ−１０産生の刺激のためのアレルゲン由来のｔ細胞抗原
MX2011008179A (es) 2009-02-05 2011-09-09 Circassia Ltd Peptidos para vacuna.
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
US9801897B2 (en) 2010-07-06 2017-10-31 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
CA2804492A1 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4226941B1 (en) 2010-08-31 2024-10-23 GlaxoSmithKline Biologicals SA Pegylated liposomes for delivery of immunogen-encoding rna
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
RS61098B1 (sr) 2012-06-15 2020-12-31 Immunomic Therapeutics Inc Nukleinske kiseline za lečenje alergija
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
JP6088584B2 (ja) * 2015-06-15 2017-03-01 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルギー治療のための核酸
JP6792847B2 (ja) * 2016-12-27 2020-12-02 国立大学法人 東京大学 ｍＲＮＡの機能化方法
EP3795688A4 (en) * 2018-05-11 2022-01-19 Astellas Pharma Inc. Nucleic acid for treating mite allergy
EP4134674A1 (en) 2021-08-13 2023-02-15 Euroimmun Medizinische Labordiagnostika AG Methods and reagents for detecting an antibody to a ses ipr-10 allergen
CN114262378B (zh) * 2021-12-20 2023-03-24 南京诺唯赞生物科技股份有限公司 一种omt的单克隆抗体及其制备方法
JP2025508467A (ja) 2022-02-24 2025-03-26 アイオー バイオテック エーピーエス 癌治療のヌクレオチド送達
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
SE9903950D0 (sv) 1999-10-29 1999-10-29 Pharmacia & Upjohn Diag Ab Non-anaphylactic forms of grass pollen allergen and their use
US20050154189A1 (en) * 2000-06-23 2005-07-14 Maxygen Inc Novel co-stimulatory molecules
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
AU2003237528A1 (en) * 2002-06-07 2003-12-22 Kentucky Bioprocessing, Llc Flexible vaccine assembly and vaccine delivery platform
ES2247433T3 (es) 2003-01-21 2006-03-01 Biomay Produktions- Und Handels- Aktiengesellschaft Procedimiento para la preparacion de proteinas de mosaico hipoalergenicas.
DE102004042546A1 (de) * 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
NZ561040A (en) * 2005-03-18 2009-04-30 Cytos Biotechnology Ag Cat allergen fusion proteins and use thereof
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines

Also Published As

Publication number Publication date
JP5535920B2 (ja) 2014-07-02
AU2008303483A1 (en) 2009-04-02
WO2009040443A1 (en) 2009-04-02
PL2200646T3 (pl) 2014-01-31
CA2700604C (en) 2016-04-26
EP2200646A1 (en) 2010-06-30
CN101827606A (zh) 2010-09-08
JP2010540500A (ja) 2010-12-24
CA2700604A1 (en) 2009-04-02
US20110033416A1 (en) 2011-02-10
EP2042193A1 (en) 2009-04-01
US20140134129A1 (en) 2014-05-15
CN101827606B (zh) 2017-08-22
ES2434221T3 (es) 2013-12-16
EP2200646B1 (en) 2013-08-07
AU2008303483B2 (en) 2013-10-31
US11020477B2 (en) 2021-06-01
DK2200646T3 (da) 2013-10-21
US20170136121A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
BRPI0817265A2 (pt) Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
SMT201600388B (it) Ligandi leganti opsina, composizioni e metodi d'uso
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
DK1926496T3 (da) PCV-2-vaccine
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
DK1968631T3 (da) Vaccine
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0821668A2 (pt) Uso
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL